PACAP (1-27), human, ovine, rat acetate (PACAP 1-27 acetate)(127317-03-7 free base) 是一种新的神经肽，最初从牛下丘脑中分离出来，也存在于人和大鼠中。

Pituitary adenylate cyclase-activating peptide (PACAP) (6-27) is a PACAP receptor antagonist with IC50 values of 1,500, 600, and 300 nM, respectively, for rat PAC1, rat VPAC1, and human VPAC2 recombinant receptors expressed in CHO cells. It binds to PACAP receptors on SH-SY5Y and SK-N-MC human neuroblastoma and T47D human breast cancer cells (IC50s = 24.5, 106, and 105 nM, respectively) and inhibits cAMP accumulation induced by PACAP (1-38) (Kis = 457, 102, and 283 nM, respectively, in SH-SY5Y, SK-N-MC, and T47D cells). In vivo, in newborn pigs, PACAP (6-27) (10 μM) inhibits vasodilation of pial arterioles induced by PACAP (1-27) and PACAP (1-38) . It also inhibits PACAP (1-27)-stimulated increases in plasma insulin and glucagon levels and pancreatic venous blood flow in dogs when administered locally to the pancreas at a dose of 500 μg.

PACAP-38 (31-38), human, mouse, rat acetate 是 PAC1 受体的激活剂。PACAP-38 (31-38), human, mouse, rat acetate 对交感神经元 NPY 和儿茶酚胺的产生具有强效、有效和持续的刺激作用，可用于神经营养和神经保护研究。

PACAP 1-38 acetate 是一种垂体腺苷酸环化酶激活多肽 (PACAP) 类似物。它与 PACAP I 型受体 (IC50 = 4 nM) 和 PACAP II 型 VIP2 受体 (IC50 = 1 nM) 结合，但不与 PACAP II 型 VIP1 受体结合。